Mitchell McLeod Pugh & Williams’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$252K Buy
+4,805
New +$254K 0.03% 280
2022
Q3
– Sell
-4,465
Closed -$243K – 231
2022
Q2
$243K Hold
4,465
– – 0.09% 188
2022
Q1
$243K Hold
4,465
– – 0.08% 203
2021
Q4
$246K Hold
4,465
– – 0.08% 206
2021
Q3
$213K Hold
4,465
– – 0.08% 211
2021
Q2
$222K Buy
+4,465
New +$215K 0.09% 210
2020
Q3
– Sell
-3,976
Closed -$203K – 200
2020
Q2
$203K Buy
+3,976
New +$204K 0.12% 178

Other funds holding GSK

Mitchell McLeod Pugh & Williams's GSK Position: Q2 2026 in Review

Mitchell McLeod Pugh & Williams opened a new position in GSK (GSK) in Q2 2026: 4,805 shares worth $252K. The stake represents 0.03% of the portfolio and ranks #280 among its holdings. This is a return to the name: Mitchell McLeod Pugh & Williams previously reported a position in GSK as recently as Q2 2022.

Mitchell McLeod Pugh & Williams first reported a position in GSK in Q2 2020 and has held it in 7 quarters since. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Mitchell McLeod Pugh & Williams held 4,805 shares of GSK worth $252K as of Q2 2026.
  • GSK was a new Mitchell McLeod Pugh & Williams position in Q2 2026.
  • GSK made up 0.03% of Mitchell McLeod Pugh & Williams's portfolio in Q2 2026, its #280 holding.
  • Mitchell McLeod Pugh & Williams first reported a position in GSK in Q2 2020 and has held it in 7 quarters since.
  • 1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Mitchell McLeod Pugh & Williams's 13F filing for Q2 2026, filed 11 Aug 2026.